《WHO儿童基本药物标准清单(第6版)》对制定我国儿童基本药物目录的参考性分析——基于34家儿童专科医院调研结果

Analysis the Reference of WHO Model List of Essential Medicines for Children( 6th list ) to Essential Medicines for Children of China——Based on 34 Children's Hospitals

目的:比较分析第6版《WHO儿童基本药物标准清单》(EMLc)与我国儿科临床用药的差异,为制定我国儿童基本药物目录提供借鉴。方法:调查34家儿童专科医院获得儿科常用活性成分清单,并与第6版EMLc、2012版基本药物目录中适宜儿童的活性成分进行对比分析。结果:获得我国儿科临床常用活性成分327种,其中有96种活性成分同时被2012版基药目录及第6版EMLc收录,28种活性成分仅被第6版EMLc收录,不同作用类别的药物在3份清单中的比例存在一定差异。结论:第6版EMLc收录的部分药物可考虑作为我国儿童基本药物候选品种,但作用类别种类及比例要充分考虑我国国情及儿科特点,综合参考EMLc及2012版基药目录。

Objective：Comparaing WHO Model List of Essential Medicines for Children（6th list）（EMLc）to medicines used in pediatric clinical,to provide reference of developing essential medicine list for children in China.Methods：Active ingredients in common use of 34 Children’s Hospitals were investigated,compared the results to 6th EMLc and National Essential Medicine List（2012edition）.Results：There are 327 active ingredients in common use in Chinese pediatric clinical.Ninety-six of them exist in both 6th EMLc and National Essential Medicine List（2012 edition）and 28 of them exist only in 6th EMLc.There are some differences in the proportions of different clinical action categories of medicines in these three lists.Conclusion：Some of medicines exist in 6th EMLc should be considered included in our essential medicine list for children,while the clinical action categories and proportion should be fully considered based on national conditions and characteristics of pediatrics.